SVRA(SVRA)
SVRA
ANALYST COVERAGE10 analysts
BUY
▲ +98.8%upside to target
PRICE
Prev Close
5.27
Open
5.15
Day Range5.02 – 5.29
5.02
5.29
52W Range1.89 – 7.01
1.89
7.01
61% of range
VOLUME & SIZE
Avg Volume
1.5M
FUNDAMENTALS
P/E Ratio
-9.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.69
Low vol
TECHNICAL
RSI (14)
47
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$1.03B
Revenue TTM$0.00
Net Income TTM-$129.48M
Free Cash Flow-$106.97M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-87.2%
Return on Assets-58.4%
Debt / Equity0.17
Current Ratio13.47
EPS TTM$-0.51
SVRA News
About
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Robert Neville
Website
Brian MaurerHead of Clinical Operations
Brian RobinsonExecutive Vice President of Global Medical Affairs
Siddharth J. AdvantExecutive Vice President of Global Technical Operations
Yasmine WasfiChief Medical Officer
Charles LaPreeExecutive Vice President & Head of Global Regulatory Affairs
David L. LowranceChief Financial & Administrative Officer and Secretary
Matthew PaulsChairman & Chief Executive Officer
Robert LutzChief Operating Officer
Anne EricksonChief Business & Corporate Affairs Officer
Kate McCabeChief Legal Officer